FeesSafety
Pluang+

Three dividend stocks yield more than the 1-year Treasury bill, offering higher income with some risk.

20 Nov 2026, 16:17 WIB
24/7 Wall Street
View Source
Bullish
Three dividend stocks yield more than the 1-year Treasury bill, offering higher income with some risk.

Pfizer, British American Tobacco, and Enbridge offer dividend yields of 6.25%, 5.81%, and 5.91% respectively, all exceeding the 4.59% yield of the 1-year Treasury bill as of November 2026. These stocks provide income from diverse sectors—healthcare, tobacco, and energy infrastructure—with solid dividend safety supported by cash flow and long payment histories. While Treasury bills offer risk-free returns, these dividend stocks carry risks like payout cuts and price volatility but compensate with higher yields. Investors should consider their risk tolerance and investment horizon when choosing between these dividend stocks and Treasury bills.

Pfizer shares are trading at USD 27.84 with a 1-day gain of 1.09% on Pluang, reflecting active investor interest despite a high sell order ratio of 91%. British American Tobacco and Enbridge also show modest price increases, with dividend yields of 5.81% and 5.92% respectively. These figures highlight the ongoing market activity in dividend stocks as of Nov 20, 2026 21:32 WIB.

More News (PFE)

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a strong track record for investors. The company faces challenges like a patent cliff, costly acquisitions, and clinical setbacks that could threaten this strea...

Company Fundamentals
Neutral
1 day ago
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite patent cliff risks.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite patent cliff risks.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a long-standing payout streak. Although the company faces challenges like a patent cliff, costly acquisitions, and clinical trial setbacks, it currently has eno...

Company Fundamentals
Neutral
1 day ago
Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer Inc. delivered strong Q3 results driven by its oncology portfolio, Eliquis, and tafamidis franchise, with Eliquis revenue growing 25.2% year-over-year to about $2.5 billion. Despite concerns about an upcoming patent expiration cycle lasting ar...

Company Fundamentals
Bullish
2 days ago
Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer beats Q3 revenue estimates, raises 2026 guidance, and shows strong margin growth.

Pfizer reported Q3 revenue of $16.58 billion, exceeding estimates by $700 million, driven by a 32% growth in launched and acquired products and an improved gross margin of about 77%. The company raised its full-year 2026 revenue guidance to $62 billi...

Analyst Insights
Bullish
2 days ago
Three overlooked dividend stocks now yield over 5%, offering strong income potential with varied risk profiles.

Three overlooked dividend stocks now yield over 5%, offering strong income potential with varied risk profiles.

Three dividend stocks in healthcare, telecom, and financials—Pfizer, Verizon, and OneMain Holdings—currently yield over 5%, attracting income investors seeking high payouts. Pfizer offers a 5.94% yield with growing drug franchises but has tight free ...

Market News
Neutral
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App